2025 Current Fiscal Year Report: Vaccines and Related Biological Products Advisory Committee

Report Run Date: 05/03/2025 03:14:29 AM

1. Department or Agency	2. Fiscal Year
Department of Health and Human Services	2025

3. Committee or Subcommittee	3b. GSA Committee No.
Vaccines and Related Biological Products Advisory Committee	1041

4. Is this New During Fiscal Year?	5. Current Charter	6. Expected Renewal Date	7. Expected Term Date
No	12/31/2023	12/31/2025	

8a. Was Terminated During FiscalYear?	8b. Specific Termination Authority	8c. Actual Term Date
No		

9. Agency Recommendation for Next FiscalYear	10a. Legislation Req to Terminate?	10b. Legislation Pending?
Continue	Not Applicable	Not Applicable

11. Establishment Authority Authorized by Law

12. Specific Establishment Authority	13. Effective Date	14. Commitee Type	14c. Presidential?
21 U.S.C. 394	12/31/1979	Continuing	No

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports No Reports for this FiscalYear

17a. Open 0 **17b. Closed** 0 **17c. Partially Closed** 0 **Other Activities** 0 **17d. Total** 0

Meetings and Dates

No Meetings

	Current FY	Next FY

18a(1). Personnel Pmts to Non-Federal Members	$0.00	$0.00
18a(2). Personnel Pmts to Federal Members	$0.00	$0.00
18a(3). Personnel Pmts to Federal Staff	$0.00	$0.00
18a(4). Personnel Pmts to Non-Member Consultants	$0.00	$0.00
18b(1). Travel and Per Diem to Non-Federal Members	$0.00	$0.00
18b(2). Travel and Per Diem to Federal Members	$0.00	$0.00
18b(3). Travel and Per Diem to Federal Staff	$0.00	$0.00
18b(4). Travel and Per Diem to Non-member Consultants	$0.00	$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	$0.00	$0.00
18d. Total	$0.00	$0.00
19. Federal Staff Support Years (FTE)	0.00	0.00

20a. How does the Committee accomplish its purpose?

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines, allergenics, and related biological products which are intended for use in the prevention, treatment, or diagnosis of human diseases, and as required, any other products for which the Food and Drug Administration has regulatory responsibility. The Committee also considers the quality and relevance of FDA's research program which provides scientific support for the regulation of these products and makes appropriate recommendations to the Commissioner of Food and Drugs.

20b. How does the Committee balance its membership?

Members are experts in immunology, allergy and allergenic diseases, molecular biology, rDNA, virology; bacteriology, parasitology, epidemiology or biostatistics, vaccine policy, vaccine safety science, federal immunization activities, vaccine development including translational and clinical evaluation programs, hypersensitivity reactions to vaccines, preventive medicine, infectious diseases, pediatrics, microbiology, and biochemistry. One member is technically qualified and identified with consumer interests and one non-voting member represents the point of view of industry.

20c. How frequent and relevant are the Committee Meetings?

The committee held 4 meetings in FY24 and estimate that this committee will hold 6 meetings in FY25. The Committee receives information regarding the scope and mission of the research programs from the Office of Vaccines Research and Review (OVRR). All discussions are related to components of the Strategic Plan and FDA's Critical Path to New Medical Products. 1. October 5, 2023 – The committee met in open session via web conference to discuss the Strain Selection for the Influenza Virus Vaccines for the 2024 Southern Hemisphere Influenza Season. Agency Action: February 14, 2024, FDA approved Fluzone Quadrivalent, southern hemisphere and Fluzone Quadrivalent High-Dose southern hemisphere for the 2024 southern hemisphere influenza season. 2. March 5, 2024 – The committee met in open session via web conference to discuss and make recommendations on the selection of strains to be included in an influenza virus vaccine for the

2024-2025 Northern Hemisphere Influenza Season. Agency Action: On July 1, 2024, FDA approved 2024-2025 Unites States Formulation of Influenza vaccines for the 2024-2025 northern hemisphere influenza season. 3. June 5, 2024 (May 16, 2024), the committee met in open session to discuss and make recommendations on the selection of the 2024-2025 Formula for COVID-19 vaccines. Agency Actions: On August 22, 2024, FDA had four regulatory actions [approval/authorizations] on COVID-19 vaccines. COVID-19 Vaccines (2024-2025 Formula) Approval of Supplements to Biological License Applications: • Spikevax (COVID-19 Vaccine, mRNA) STN 125752/220 – Strain change to 2024-2025 Formula for use as a single dose in individuals 12 years of age and older • Comirnaty (COVID-19 Vaccine, mRNA) STN 125742/564 – Strain change to 2024-2025 Formula for use as a single dose in individuals 12 years of age and older Authorization of Amendments to the Emergency Use Authorizations: • EUA 27034, Pfizer-BioNTech COVID-19 Vaccine - Use of Pfizer-BioNTech COVID-19 Vaccine (2024-2025 Formula) in individuals 6 months through 11 years of age. • EUA 27034, Moderna COVID-19 Vaccine - Use of Moderna COVID-19 Vaccine (2024-2025 Formula) in individuals 6 months through 11 years of age. August 30, 2024 Authorization of Amendments to the Emergency Use Authorizations: • EUA 28237, Novavax COVID-19 Vaccine, Adjuvanted COVID-19 Vaccine - Use of Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) in individuals 12 years of age and older. 4. September 20, 2024-Topic I, the committee will meet in open session to discuss considerations related to the use of pertussis controlled human infection models [CHIMs] in clinical development of new pertussis vaccines.

Topic II, the committee will meet in open session to hear an overview of the research programs of the Laboratory of Mucosal Pathogens and Cellular Immunology (LMPCI), Division of Bacterial, Parasitic and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR).
Agency Action: The Agency is discussing next steps following VRBPAC recommendations.

20d. Why can't the advice or information this committee provides be obtained elsewhere?
Members of the Committee are drawn from academia, research, and/or clinical practice. They provide advice and input that FDA considers as part of its regulatory decision-making process. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at maximum rates of compensation.

20e. Why is it necessary to close and/or partially closed committee meetings?
There was one closed meeting to report for FY2024. The meeting was closed in accordance with 21 CFR section 14.27 (b), implementing 5 USC 552b(c)6), for the review of matters that would constitute a clearly unwarranted invasion of personal privacy if disclosed.

21. Remarks
No reports are required for this committe. The September 20, 2024, meeting minutes have not been finalized as of the completion of this report. We will provide it as soon as its finalized.

Designated Federal Officer
Sussan Paydar Designated Federal Officer, DSAC, Center for Biologics Evaluation and Research, FDA

Committee Members	Start	End	Occupation	Member Designation
Berger, Adam	02/01/2022	01/31/2026	National Instituters of Health	Regular Government Employee (RGE) Member
Bernstein, Henry	02/01/2022	01/31/2026	Cohen Children’s Medical Center	Special Government Employee (SGE) Member
Chatterjee, Archana	06/21/2019	01/31/2027	Chair and Dean, Department of Pediatrics, University of South Dakota	Special Government Employee (SGE) Member
El Sahly, Hana	06/10/2016	01/31/2026	Professor/Baylor College Of Medicine	Special Government Employee (SGE) Member
Gans, Hayley	06/21/2019	01/31/2027	Professor, Department of Pediatrics, Stanford University Medical Center	Special Government Employee (SGE) Member
Janes, Holly	06/10/2016	01/31/2025	Associate Member, Fred Hutchinson Cancer Research Center	Special Government Employee (SGE) Member
Jodar, Luis	02/01/2024	01/31/2028	Chief Medical Officer, Senior Vice President, Pfizer	Representative Member
Monto, Arnold	02/01/2022	01/31/2026	Professor/University of Michigan	Special Government Employee (SGE) Member
Offit, Paul	02/01/2018	01/31/2025	Physician - Children's Hospital of Philadelphia	Special Government Employee (SGE) Member
Perlman, Stanley	08/23/2022	01/31/2026	Physician - University of Iowa	Special Government Employee (SGE) Member
Portnoy, Jay	02/01/2022	01/31/2025	Director, Division of Allergy/Asthma/Immunology, The Children’s Mercy Hospital	Representative Member
Rubin, Eric	02/01/2022	01/31/2026	Adjunct Professor, Harvard, TH Chan school of Public Health	Special Government Employee (SGE) Member
Shane, Andrea	02/01/2018	01/31/2025	Physician - Emory University School of Medicine	Special Government Employee (SGE) Member

Number of Committee Members Listed: 13

Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tabacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Vaccines and Related Biological Products Advisory Committee supports FDA's mission and strategic action plan by reviewing and evaluating available data relating to the safety and effectiveness of vaccines and related biological products, which are intended for, use in the prevention, treatment, or diagnosis of human diseases. The Committee also considers the quality and relevance of FDA's research programs which provides scientific support for the regulation of these products. The Committee supports FDA's mission by using science-based efficient risk management in all of its activities. The Committee recommendations provide the most health promotion and protection at the least cost for the public. This Committee assists the Agency in ensuring timely, high quality, cost-effective processes for review of new technologies/pre-market submissions, effective communication and working relationships with stakeholders to enhance U.S. and global health outcomes, accurately analyzing risks associated with medical products, facilitating the development and availability of medical countermeasures to limit the effects of a terrorist attack on the civilian and military populations, protecting the safety and security of biologics, especially vaccines, all key components of FDA's strategic plan objectives.

What are the most significant program outcomes associated with this committee?

	Checked if Applies
Improvements to health or safety	✓
Trust in government	✓
Major policy changes	✓
Advance in scientific research	✓
Effective grant making	
Improved service delivery	
Increased customer satisfaction	✓
Implementation of laws or regulatory requirements	✓
Other	

Outcome Comments

NA

What are the cost savings associated with this committee?

	Checked if Applies
None	
Unable to Determine	✓
Under $100,000	
$100,000 - $500,000	
$500,001 - $1,000,000	
$1,000,001 - $5,000,000	
$5,000,001 - $10,000,000	
Over $10,000,000	
Cost Savings Other	

Cost Savings Comments

The utilization of the Vaccines and Related Biological Products Advisory Committee enables the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of the public health for which it is difficult to assign a financial value.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

Number of Recommendations Comments
The Committee made approximately 143 recommendations from FY2003 through FY2024.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?
84%

% of Recommendations Fully Implemented Comments
The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?
10%

% of Recommendations Partially Implemented Comments
The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?
Yes ✓ No ☐ Not Applicable ☐

Agency Feedback Comments
When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	✓
Reallocated resources	✓

Issued new regulation	✓
Proposed legislation	☐
Approved grants or other payments	☐
Other	✓

Action Comments

FDA approves or chooses not to approve a new medical product or other regulatory decision-making.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	✓
Online Agency Web Site	✓
Online Committee Web Site	✓
Online GSA FACA Web Site	✓
Publications	✓
Other	☐

Access Comments

N/A